[A21-24] Esketamine (depression) - Benefit assessment according to §35a Social Code Book V
Last updated 01.06.2021
Project no.:
A21-24
Commission:
Commission awarded on 03.03.2021 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Mental and emotional wellbeing
Adults with treatment-resistant major depressive disorder, who have not responded to at least two different treatments with antidepressants in the current moderate to severe depressive episode
Added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A21-25 | Esketamine (depression, acute treatment) - Benefit assessment according to §35a Social Code Book V | Commission completed |